Researchers from The University of Texas MD Anderson Cancer Center and Sarah Cannon Research Institute have used ripretinib and surgical removal of a tumour to successfully treat a patient with recurring gastrointestinal cancer, carrying a KIT exon 11 mutation. The patient received 43 months of treatment, longer than current ripretinib clinical trials, which are reported to have improved clinical outcomes.
Health Tech | Safeguarding health: Navigating the complex landscape of cybersecurity in healthcare | News
The integration of technology in healthcare, while beneficial, has increased the sector’s vulnerability to cyber threats. Cybercriminals target healthcare data due to its high value,